Transplantation Site Affects the Outcomes of Adipose-Derived Stem Cell-Based Therapy for Retinal Degeneration.
Journal
Stem cells international
ISSN: 1687-966X
Titre abrégé: Stem Cells Int
Pays: United States
ID NLM: 101535822
Informations de publication
Date de publication:
2020
2020
Historique:
received:
22
08
2019
revised:
22
10
2019
accepted:
03
12
2019
entrez:
8
5
2020
pubmed:
8
5
2020
medline:
8
5
2020
Statut:
epublish
Résumé
Adipose-derived stem cells (ASCs) have shown a strong protective effect on retinal degenerative diseases (RDD) after being transplanted into the subretinal space in an animal model. Recently, several clinical trials have been conducted to treat RDD with intravitreal transplantation of stem cells, including ASCs. However, the outcomes of the clinical trials were not satisfactory. To investigate if the transplantation site alters the outcome of stem cell-based therapy for RDD, we isolated rat ASCs (rASCs) and labeled them with green fluorescent protein. Autologous rASCs were grafted into the vitreous chamber or subretinal space in a rat RDD model induced by sodium iodate (SI). The electric response was recorded by ERG. The anatomic structure of the retina was observed in cryosections of rat eyes at posttransplantation weeks 1, 2, and 4. Neural retina apoptosis and epiretinal membrane- (ERM-) like structure formation were investigated by immunostaining. The intravitreal transplantation of rASCs resulted in an extinguished electric response, although the rosette formation and apoptosis of neural retina were reduced. However, the rASCs that grafted in the subretinal space protected the retina from the damage caused by SI, including a partial recovering of the electric response and a reduction in rosette formation. Intravitreally grafted rASCs formed a membrane, resulting in retina folding at the injection site. Müller cells, retinal pigment epithelial cells, and microglial cells migrated from the retina to the rASC-formed membrane and subsequently formed an ERM-like structure. Furthermore, vitreous fluid promoted rASC migration, and rASC-conditioned medium enhanced Müller cell migration as indicated by in vitro studies. These data suggested that the vitreous chamber is not a good transplantation site for ASC-based therapy for RDD and that a deliberate decision should be made before transplantation of stem cells into the vitreous chamber to treat RDD in clinical trials.
Identifiants
pubmed: 32377204
doi: 10.1155/2020/9625798
pmc: PMC7199575
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9625798Informations de copyright
Copyright © 2020 Chengyu Hu et al.
Déclaration de conflit d'intérêts
All the authors indicate no potential conflict of interest.
Références
Cytotherapy. 2009;11(2):177-88
pubmed: 19241195
Acta Ophthalmol. 2019 Jun;97(4):e580-e588
pubmed: 30561135
Int J Mol Sci. 2012;13(1):1239-57
pubmed: 22312315
Invest Ophthalmol Vis Sci. 2014 Jan 03;55(1):55-63
pubmed: 24222300
F1000 Biol Rep. 2010 Nov 11;2:78
pubmed: 21170369
Ophthalmic Surg. 1992 Feb;23(2):116-9
pubmed: 1549287
Biochimie. 2013 Dec;95(12):2222-8
pubmed: 23770442
Prog Retin Eye Res. 2006 Mar;25(2):149-64
pubmed: 16377232
Invest Ophthalmol Vis Sci. 2016 Aug 1;57(10):4144-50
pubmed: 27537264
J Invest Dermatol. 2017 Feb;137(2):e11-e16
pubmed: 28110712
Arch Ophthalmol. 1995 Mar;113(3):359-63
pubmed: 7887851
Am J Ophthalmol. 1983 Sep;96(3):345-53
pubmed: 6351623
Stem Cell Res Ther. 2019 Aug 7;10(1):242
pubmed: 31391108
Retina. 2019 Jun;39(6):1061-1065
pubmed: 30964781
Retina. 2017 Mar;37(3):417-423
pubmed: 27753762
PLoS One. 2015 Apr 07;10(4):e0122229
pubmed: 25849436
Brain Res. 2016 Nov 15;1651:1-10
pubmed: 27641993
Tissue Eng. 2001 Apr;7(2):211-28
pubmed: 11304456
Br J Haematol. 2010 Feb;148(3):428-40
pubmed: 19863541
Tissue Cell. 2019 Feb;56:52-59
pubmed: 30736904
Int J Mol Sci. 2018 Jul 05;19(7):
pubmed: 29976859
Rom J Ophthalmol. 2015 Apr-Jun;59(2):74-7
pubmed: 26978865
Curr Mol Med. 2016;16(6):553-66
pubmed: 27280496
PLoS One. 2014 Jan 23;9(1):e86865
pubmed: 24466271
Prog Retin Eye Res. 2016 Mar;51:125-55
pubmed: 26209346
N Engl J Med. 2017 Mar 16;376(11):1047-1053
pubmed: 28296617
Am J Ophthalmol. 2005 Aug;140(2):288-94
pubmed: 16023066
Retin Cases Brief Rep. 2017 Summer;11(3):227-231
pubmed: 27171917
Lab Invest. 2004 Aug;84(8):963-72
pubmed: 15156160
Ophthalmic Surg Lasers Imaging Retina. 2017 Sep 1;48(9):772-775
pubmed: 28902341
Curr Mol Med. 2016;16(6):567-81
pubmed: 27280495
Graefes Arch Clin Exp Ophthalmol. 2009 Jul;247(7):865-83
pubmed: 19415318
Int J Retina Vitreous. 2019 Feb 13;5:7
pubmed: 30805203
Exp Eye Res. 2019 Oct;187:107755
pubmed: 31408630
Ophthalmic Surg Lasers Imaging Retina. 2019 Feb 1;50(2):125-131
pubmed: 30768222
Curr Mol Med. 2013 Nov;13(9):1419-31
pubmed: 23971737
Stem Cell Res Ther. 2017 Dec 22;8(1):290
pubmed: 29273085
Stem Cells Int. 2018 Dec 13;2018:9682856
pubmed: 30651740
Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6506-14
pubmed: 26447986
Curr Mol Med. 2017;17(6):421-435
pubmed: 29210653
Exp Clin Transplant. 2018 Apr;16(2):204-211
pubmed: 29025379
Curr Eye Res. 2019 Nov;44(11):1236-1243
pubmed: 31199706
Ophthalmic Surg Lasers Imaging Retina. 2016 Jun 1;47(6):600-1
pubmed: 27327294
Acta Pharmacol Toxicol (Copenh). 1979 Apr;44(4):241-50
pubmed: 433617
Biochim Biophys Acta. 1963 Jan 1;69:58-67
pubmed: 14001595
Mol Vis. 2011;17:1794-805
pubmed: 21750605
Int Ophthalmol. 2016 Oct;36(5):713-8
pubmed: 26857724
Stem Cell Rev Rep. 2016 Feb;12(1):26-41
pubmed: 26490462